Sol-Gel Technologies Ltd. (SLGL): Depreciation & Amortization
$109.0K
Year ended 2025-12-31
-42.1%
3-year compound annual growth
-35.1%
5-year compound annual growth
-9.6%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $109.0K | -53.2% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $233.0K | -31.9% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $342.0K | -39.1% | 2026-03-19, From 2023-01-01 |
| 2022-12-31 | $562.0K | -36.1% | 2025-04-29, From 2022-01-01 |
| 2021-12-31 | $880.0K | -7.0% | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | $946.0K | +6.7% | 2023-03-10, From 2020-01-01 |
| 2019-12-31 | $887.0K | +16.4% | 2022-04-07, From 2019-01-01 |
| 2018-12-31 | $762.0K | +61.8% | 2021-03-04, From 2018-01-01 |
| 2017-12-31 | $471.0K | +31.2% | 2020-03-24, From 2017-01-01 |
| 2016-12-31 | $359.0K | +19.7% | 2019-03-21, From 2016-01-01 |
| 2015-12-31 | $300.0K | n/a | 2018-03-26, From 2015-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $109.0K | -53.2% |
| Scynexis Inc (SCYX) | 2024-12-31 | $0 | -100.0% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $1.20M | -7.7% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $220.0K | +94.7% |
| uniQure N.V. (QURE) | 2025-12-31 | $14.76M | +16.8% |
| Alumis Inc. (ALMS) | 2025-12-31 | $3.50M | +10.9% |
| Celularity Inc (CELU) | 2025-12-31 | $7.29M | -7.9% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $4.51M | +51.3% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $192.0K | -42.5% |
Compare SLGL, SCYX, CASIF, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗